Company Genocea Biosciences Inc Nasdaq
Equities
US3724271040
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2020 | Weight | 2021 | Weight | Delta |
---|---|---|---|---|---|
Cancer Immunotherapies
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +20.75% |
Sales per region
USD in Million | 2020 | Weight | 2021 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +20.75% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 52 | 07-02-28 | |
Girish Aakalu
PRN | Corporate Officer/Principal | - | 18-12-09 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 14-09-10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 58,783,503 | 58,783,503 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Genocea Biosciences, Inc.
Cambridge Discovery Park 100 Acorn Park Drive
02140, Cambridge
+617 876 8191
http://www.genocea.comSector
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |